论文部分内容阅读
自1957年美国国立癌症研究所首先提出生物学应答调节剂(BRM)新概念,进而将它纳入生物学治疗的范畴以来,有计划的研究虽仅十余年,但进展十分迅速。BRM 的应用始开抗癌,但绝不限于抗癌,它对感染(包括慢病毒、寄生虫感染)、免疫缺陷(包括艾滋病)、免疫介异疾病等的防治,以至抗衰老、保健等等都有着重要的价值。近年来国际制药界出现了新的观点,改变了目前一味认为生物制药是尖端,理想的制药模式,趋向于小分子药物的开发。小分子合成药免疫调节剂左旋咪唑搽剂的研究开发及临床
Since the first attempt by the National Cancer Institute in 1957 to introduce a new concept of biological response modifier (BRM) to include biologic therapies, there have been more than ten years of planned research but progress has been rapid. The application of BRM has started anti-cancer, but by no means limited to anti-cancer, its prevention and treatment of infection (including lentivirus, parasitic infection), immunodeficiency (including AIDS), immune-mediated diseases, as well as anti-aging, health care, etc. All have important value. In recent years, the international pharmaceutical industry has emerged a new perspective, changing the current blindly think that biopharmaceuticals are cutting-edge, ideal pharmaceutical model, the development of small molecule drugs tend to. Research and development of small molecule synthetic immunosuppressant levamisole liniment and its clinical application